Histogenics (NSDQ:HSGX) said last week that its board of directors approved a restructuring plan that would result in layoffs for all but one of the company’s employees. The layoffs include CEO Adam Gridley and COO Stephen Kennedy. Gridley and Kennedy plan to evaluate “strategic alternatives” for the company in consulting capacities alongside up to four other […]
Histogenics to lay off 65% of workforce, including CMO & CBO, in restructuring
Histogenics (NSDQ:HSGX) said today that its board of directors approved a restructuring plan with a 65% reduction in its workforce, including the the company’s chief medical officer Dr. Lynne Kelley and chief business officer Donald Haut, according to an SEC filing. The move comes after the Waltham, Mass.-based company decided to discontinue development of its NeoCart product […]
Histogenics plunges on missed endpoint in NeoCart trial
UPDATE: Now includes comment from CEO Adam Gridley Histogenics (NSDQ:HSGX) said today that a pivotal trial of its regenerative NeoCart knee treatment failed to meet its primary endpoint, sending its share price down some -70%. Waltham, Mass.-based Histogenics said NeoCart, which is designed to repair knee cartilage damage using cells harvested from the surface of patients’ […]
Histogenics inks $10 stock sale deal, beats the Street with Q4, 2017 earnings
Histogenics (NSDQ:HSGX) today announced a $10 million sale deal and released its fourth quarter and full year 2017 earnings, seeing shares fall as losses grew, despite the company beating The Street with its loss-per-share numbers. The company said it inked an equity distribution agreement with Cannacord Genuity to sell up to $10 million, with Cannacord acting as […]
Histogenics inks deal to develop Neocart for the Japanese market
Histogenics (NSDQ:HSGX) has inked a deal with Medinet to develop and commercialize its Neocart implant for the Japanese market. The Waltham, Mass.-based company’s Neocart implant is designed to repair knee cartilage damage. The product is made using a patient’s own cells, harvested from the surface of the patient’s femur. Get the full story at our sister site, Drug […]
Relievant Medsystems taps ex-Cameron Health chief Hykes for CEO | Personnel Moves, Sept. 26, 2017
Relievant Medsystems said it named former Cameron Medical chief Kevin Hykes to be its new CEO, effective immediately. Hykes, who led Cameron Health to a $1.35 billion buyout in 2012 by Boston Scientific (NYSE:BSX), replaced Alex DiNello, who was named COO, Relievant said. Relievant makes the Intracept device for treating lower back pain. Hykes was most recently […]
Histogenics finishes trial planning in pursuit of Japanese NeoCart approval
Histogenics (NSDQ:HSGX) said today it completed all formal consultations with the Japanese Pharmaceuticals and Medical Devices Agency’s Office of Cellular and Tissue-based Products as it seeks regulatory clearance for its NeoCart in Japan. NeoCart is designed to stimulate the body’s ability to regenerate cartilage in the knee, using neocartilagenous tissue developed from patients’ chondrocyte cells, the Waltham, […]
Histogenics raises $30m for NeoCart regenerative knee treatment
Histogenics (NSDQ:HSGX) said last month that it raised $30 million in a private placement it plans to use for a pivotal trial of its NeoCart regenerative knee treatment. The Waltham, Mass.-based company said the round, of equity, convertible stock and warrants, was led by new institutional investors and some of its existing backers. The cash […]
Histogenics inks supply deal with Collagen Solutions
Regenerative medicine-focused Histogenics said Wednesday it signed a supply deal with U.K.-based Collagen Solutions. Collagen Solutions will provide collagen material sources for use in Histogenics investigational NeoCart which is being designed to repair knee cartilage damage. The NeoCart product is currently in phase 3 trials. “Collagen Solutions has again demonstrated that it can provide materials […]
GI Dynamics axes medical chief Maggs | Personnel Moves
GI Dynamics (ASX:GID) said last week in a regulatory filing that it fired chief medical officer Dr. David Maggs “for cause.” The Lexington, Mass.-based medical device company did not otherwise elaborate on the reason for Maggs’s departure, which was effective June 18, according to the filing. Maggs joined GI Dynamics in April 2013 to oversee the clinical […]
Histogenics sets range for $60m IPO
Histogenics set the per-share price range on its forthcoming initial public offering at $13 to $15 per share.
That puts the mid-point for the nearly 4.3 million-share offering at just under $60 million.
MassDevice Network
@MassDevice
LinkedIn
YouTube